RT Journal Article SR Electronic T1 Sequencing SARS-CoV-2 Genomes from Saliva JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.06.21.21259289 DO 10.1101/2021.06.21.21259289 A1 Alpert, Tara A1 Vogels, Chantal B.F. A1 Breban, Mallery I. A1 Petrone, Mary E. A1 Yale IMPACT Research Team A1 Wyllie, Anne L. A1 Grubaugh, Nathan D. A1 Fauver, Joseph R. YR 2021 UL http://medrxiv.org/content/early/2021/06/29/2021.06.21.21259289.abstract AB Genomic sequencing is crucial to understanding the epidemiology and evolution of SARS-CoV-2. Often, genomic studies rely on remnant diagnostic material, typically nasopharyngeal swabs, as input into whole genome SARS-CoV-2 next-generation sequencing pipelines. Saliva has proven to be a safe and stable specimen for the detection of SARS-CoV-2 RNA via traditional diagnostic assays, however saliva is not commonly used for SARS-CoV-2 sequencing. Using the ARTIC Network amplicon-generation approach with sequencing on the Oxford Nanopore MinION, we demonstrate that sequencing SARS-CoV-2 from saliva produces genomes comparable to those from nasopharyngeal swabs, and that RNA extraction is necessary to generate complete genomes from saliva. In this study, we show that saliva is a useful specimen type for genomic studies of SARS-CoV-2.Competing Interest StatementN.D.G. is a consultant for Tempus Labs for infectious disease genomics. All other authors declare no competing interests.Funding StatementThis work was funded by CTSA Grant Number TL1 TR001864 (T.A.), a fast grant from Emergent Ventures at the Mercatus Center at George Mason University (N.D.G.), and Centers for Disease Control and Prevention (CDC) contracts 75D30120C09570 (N.D.G.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Nasopharyngeal swabs and saliva were collected from enrolled COVID-19 inpatients and healthcare workers from Yale-New Haven Hospital in accordance with the Yale University HIC-approved protocol #2000027690. Samples were collected after the study participant had acknowledged that they had understood the study protocol and signed the informed consent. All participant information and samples were collected in association with non-individually identifiable study identifiers. These samples were used to create the Yale COVID-19 Biorepository. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll consensus genomes used in this study have been deposited at https://github.com/josephfauver/Saliva_Sequencing_Manuscript and are publicly available as of the date of publication. Accession numbers are listed in the key resources table. All original code has been deposited at https://github.com/josephfauver/Saliva_Sequencing_Manuscript and is publicly available as of the date of publication. https://github.com/josephfauver/Saliva_Sequencing_Manuscript